PubMed Health⌕ Search

Biomedical subjects

W Simonds

Publications and source records attributed to W Simonds.

7 recordsLinked to original sources
PubMed2000

In-depth interviews with medical abortion clients: thoughts on the method and home administration of misoprostol.

OBJECTIVE: To document women's experiences with a home-use mifepristone-misoprostol medical abortion regimen. METHODS: We conducted in-depth interviews (n = 22) with women who received abortions in the New York City clinic of the ongoing Abortion Rights Mobilization clinical trial. Women received 200 micrograms mifepristone in the clinic and were randomized to self-administer 800 micrograms misoprostol vaginally at home either 24, 48, or 72 hours later. One week later, after their follow-up visits, women were asked to describe their experiences in their own words. RESULTS: The overwhelming majority of women found the home-use regimen acceptable. Nearly all said that they would not have preferred to return to the clinic for misoprostol, and many stated that the home-use option was the principal appeal of medical abortion. Women described the medical procedure as "natural," private, and noninvasive, and, when describing their physical experiences, noted that the side effects were more tolerable in the comfort of their homes with someone familiar nearby for support. Additionally, most women felt prepared for the experience they encountered and competent in assessing any problems that arose. CONCLUSION: Home use of misoprostol affords women more flexibility, privacy, and control in their abortions, ultimately allowing them to seek their own comfort level.

Abortifacient Agents, Nonsteroidal↗
PubMed1999

Providing mifepristone-misoprostol medical abortion: the view from the clinic.

In order to gather information about the practical aspects of offering medical abortion, we conducted focus group discussions at each of 17 sites participating in the first large-scale, multi-center trial of mifepristone-misoprostol abortion in the United States. The sites were chosen to represent diverse practice settings (Planned Parenthood affiliates, university research clinics, private practices, and feminist health centers) and geographical regions. Seventy-seven clinic staff members (including counselors, administrators, physicians and other health workers) participated. They discussed the impact of adding a medical method to their clinic structure, their own preferences about offering the method, and their perceptions of women's preferences. Staffing a medical abortion service requires different skills and temperament than those needed for a surgical service. Nearly all participants were eager to begin offering the medical method, and they perceived a strong demand for it on the part of women. They had mixed feelings about the type of provider who should offer the method, but nearly all felt that the regimen could be greatly simplified from the three-visit regimen tested in the trial.

Abortifacient Agents↗
PubMed1998

Abortion, revised: participants in the U.S. clinical trials evaluate mifepristone.

This paper centers on the questions: How do non-surgical abortion methods affect private experiences of abortions? How might they influence public conceptions of abortion? Drawing on interviews with clients who participated in the 1994-95 U.S. clinical trials of mifepristone at one trial site (conducted during the trials), and focus group interviews conducted with health care workers at all 17 trial sites (after the trials were completed), we examine participants' evaluations of this method of abortion. Surgical abortion functioned as the reference point by which research participants assessed medical abortion. They discussed mifepristone abortion in terms of nature and invasion, privacy and bodily integrity, denial and agency. Clients frequently portrayed mifepristone abortion as a better moral choice than surgical abortion--in some cases even depicting it as not-really-an-abortion but rather as a miscarriage. Clients felt that mifepristone offered them a greater measure of control over their abortion experiences. Health care providers offered critical analysis of their clients' perceptions, yet affirmed the potential of medical abortion to offer women greater variety and latitude in procreative decision-making, and perhaps even to depoliticize the issue of abortion in the U.S. by thwarting the efforts of anti-abortionists to target providers and aborting women.

Abortifacient Agents, Steroidal↗
PubMed1988

Identification of the GTP-binding protein encoded by Gi3 complementary DNA.

Three closely related, but distinct, GTP-binding proteins (G-proteins) are encoded by cDNAs arbitrarily designated Gi1, Gi2, and Gi3. The in vitro translated products of mRNAs prepared from Gi1, Gi2, and Gi3 cDNAs migrate as 41-, 40-, and 41-kDa proteins, respectively, on sodium dodecyl sulfate-polyacrylamide gels. Antisera were raised against synthetic decapeptides corresponding to a divergent sequence (residues 159-168 for Gi1 and Gi3; 160-169 for Gi2) of the three cDNAs and tested on immunoblots for reactivity with three purified G-proteins, G41 and G40 from brain and G41 from HL-60 cells. LD antisera (Gi1 peptide) react only with brain G41. LE antisera (Gi2 peptide) react only with brain G40, and SQ antisera (Gi3 peptide) react exclusively with HL-60 G41. The results indicate that the 41-kDa G-protein purified from HL-60 cells differs from the purified brain 41-kDa protein and suggest that the HL-60 cell protein corresponds to that encoded by Gi3 cDNA.

Amino Acid Sequence↗